Men taking statin drugs had a modest reduction in prostate growth in a new analysis of a 4-year, large, randomized trial of the dual 5-alpha-reductase inhibitor dutasteride (Avodart) versus placebo for risk reduction of prostate cancer among high-risk men.
Men with moderate to severe lower urinary tract symptoms associated with BPH obtained significant symptom relief with the phosphodiesterase type-5 inhibitor tadalafil (Cialis) and the alpha-blocker tamsulosin (Flomax), both of which also improved urinary flow, results of a randomized trial showed.
Adoption of robotic surgery for treatment of kidney cancer has led to a modest increase in the annual volume of partial nephrectomies but a substantial cost savings for care of chronic kidney disease, an economic analysis of a 6-year period suggests.
Older patients with early-stage kidney cancer had significant improvement in short-term survival after partial versus radical nephrectomy but no long-term survival benefit, data from a large retrospective study showed.
Patients with early-stage kidney cancer fared much better with partial rather than radical nephrectomy if they were candidates for either procedure, say researchers from the University of Michigan, Ann Arbor.
One-third of men with high-risk prostate cancer achieved pathologic complete response (pCR) or near-complete response to 6 months of preoperative therapy with abiraterone acetate (ZYTIGA), leuprolide, and prednisone, investigators reported at the American Society of Clinical Oncology annual meeting in Chicago.
Functional recovery after partial nephrectomy correlated more closely with volume loss than with warm ischemia time, researchers from Cleveland Clinic's Glickman Urological and Kidney Institute recently reported.